Biology
Autoimmune Pathogenesis of Rheumatoid Arthritis
Quick fact
Rheumatoid arthritis is an autoimmune disease that affects about 1% of the world's population, with women being affected about three times more often than men.
Why this is interesting
Your immune system is supposed to defend you from invaders, but in rheumatoid arthritis it turns against your own joints. Why would the body's defenders attack its own tissue, and what can we do to stop them?
Read the full explanation
Understanding Autoimmune Pathogenesis of Rheumatoid Arthritis
Imagine your immune system as a highly trained security force. Its job is to identify and eliminate harmful invaders like bacteria and viruses. But in rheumatoid arthritis, something goes wrong—the security force mistakenly identifies the lining of your joints (the synovium) as a threat. This lining normally produces fluid that lubricates the joint, but when attacked, it becomes inflamed, swollen, and painful. Over time, the ongoing attack damages the cartilage and bone within the joint. The process is chronic, meaning it doesn't resolve, but instead continues over years, causing progressive damage. Why does the immune system turn against our own tissues? It's a combination of genetic predisposition and environmental triggers that cause a breakdown in self-tolerance. Self-tolerance is the immune system's ability to recognize 'self' and not attack it. When this tolerance fails, immune cells (like T cells and B cells) that are autoreactive—meaning they react to our own proteins—become activated and begin attacking the joints.
A deeper explanation
The autoimmune pathogenesis of rheumatoid arthritis involves a complex interplay between genetics, environment, and immune dysregulation. A key genetic factor is the HLA (human leukocyte antigen) class II allele, especially HLA-DR4, which is important for presenting peptides to T cells. Certain HLA-DR4 variants can present self-peptides in a way that triggers an autoimmune response. Environmental factors, such as smoking, can increase the risk, possibly by modifying proteins (citrullination) in the lungs, creating new autoantigens. This process, called citrullination, is mediated by peptidylarginine deiminases (PADs). Interestingly, the body produces antibodies against these citrullinated proteins (anti-CCP antibodies) years before clinical symptoms appear, suggesting a loss of tolerance early on. Once autoreactive T cells are activated, they migrate to the synovium and release pro-inflammatory cytokines like TNF-α and IL-6. These cytokines recruit more immune cells (macrophages, B cells) and trigger synovial proliferation, forming a structure called pannus. The pannus invades cartilage and bone, leading to erosions. B cells produce autoantibodies (like rheumatoid factor and anti-CCP), which form immune complexes in the joint, further perpetuating inflammation. This self-sustaining cycle of inflammation and tissue damage is the hallmark of RA. Understanding this mechanism is why targeted therapies, like TNF inhibitors and IL-6 blockers, are effective: they interrupt specific points in the inflammatory cascade, even if we cannot yet cure the underlying loss of tolerance.